Prostate cancer: Multiparametric mri for index lesion localization - A multiple-reader study

American Journal of Roentgenology

Volumn 199, Issue 4, 2012, Pages 830-837

  Rosenkrantz, Andrew B ^a   Deng, Fang Ming ^b   Kim, Sooah ^a   Lim, Ruth P ^a   Hindman, Nicole ^a   Mussi, Thais C ^a,c   Spieler, Bradley ^a,d   Oaks, Jason ^a,e   Babb, James S ^a   Melamed, Jonathan ^b   Taneja, Samir S ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e DEWITT ARMY COMMUNITY HOSPITAL   (United States)

Author keywords

Diffusion weighted MRI; Dynamic contrast enhanced MRI; Prostate cancer; T2 weighted MRI

Indexed keywords

GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; INDEX LESION LOCALIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETRIC TEST; PATHOLOGIST; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOLOGIST; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84866872444     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.8446     Document Type: Article

References (55)

1. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-1319
2. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352:1977-1984 (Pubitemid 40638368)
3. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-1328
4. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28:126-131
5. Krakowsky Y, Loblaw A, Klotz L. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol 2010; 184:131-135
6. Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 2007; 178:2260-2267 (Pubitemid 350052204)
7. Ahmed HU, Emberton M. Is focal therapy the future for prostate cancer? Future Oncol 2010; 6:261-268
8. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007; 4:632-642 (Pubitemid 350020378)
9. Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol 2009; 18:219-232
10. Ahmed HU, Zacharakis E, Dudderidge T, et al. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer 2009; 101:19-26
11. Bahn DK, Silverman P, Lee F Sr, Badalament R, Bahn ED, Rewcastle JC. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol 2006; 20:688-692 (Pubitemid 46140997)
12. Lecornet E, Ahmed HU, Moore CM, Emberton M. Conceptual basis for focal therapy in prostate cancer. J Endourol 2010; 24:811-818
13. Rukstalis DB, Goldknopf JL, Crowley EM, Garcia FU. Prostate cryoablation: a scientific rationale for future modifications. Urology 2002; 60:19-25 (Pubitemid 36153110)
14. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15:559-565
15. Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010; 106:1607-1611
16. Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2011; 14:46-52
17. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60:264-269 (Pubitemid 34831770)
18. Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 2003; 170:459-463 (Pubitemid 36870224)
19. Ohori M, Eastham JA, Koh H. Is focal therapy reasonable in patients with early stage prostate cancer (CAP): an analysis of radical prostatectomy (RP) specimens. J Urol 2006; 175(suppl):507
20. Davis JW, Kim J, Ward JF, et al. Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci. BJU Int 2010; 105:1386-1391
21. Mufarrij P, Sankin A, Godoy G, Lepor H. Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology 2010; 76:689-692
22. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011; 186:1818-1824
23. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257:715-723
24. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006; 239:784-792 (Pubitemid 43830614)
25. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010; 255:89-99
26. Tareen B, Godoy G, Sankin A, Temkin S, Lepor H, Taneja SS. Laterality alone should not drive selection of candidates for hemi-ablative focal therapy. J Urol 2009; 181:1082-1089; discussion 1089-1090
27. Fine SW, Epstein JI. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 2008; 179:1335- 1338; discussion 1338-1339
28. Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005; 48:895-899 (Pubitemid 41641631)
29. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004; 64:544-550 (Pubitemid 39200755)
30. Rosenkrantz AB, Mendrinos S, Babb JS, Taneja SS. Prostate cancer foci detected on multiparamtric MRI are histologically distinct from those not detected. J Urol 2012; 187:2032-2038
31. Langer DL, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2 - sparse versus dense cancers. Radiology 2008; 249:900-908
32. Ward JF, Nakanishi H, Pisters L, Babaian RJ, Troncoso P. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 2009; 104:490-497
33. Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186:1281-1285
34. Kaji Y, Kurhanewicz J, Hricak H, et al. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 1998; 206:785-790 (Pubitemid 28128531)
35. White S, Hricak H, Forstner R, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995; 195:385-390
36. Vilanova JC, Comet J, Barcelo-Vidal C, et al. Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: detection with MR imaging and MR spectroscopy. Radiology 2009; 253:135-143
37. Vilanova JC, Barcelo-Vidal C, Comet J, et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostatespecific antigen ratio in the detection of prostate cancer. AJR 2011; 196:1299; [web]W715-W722
38. Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011; 108:E171-E178
39. Schiebler ML, Schnall MD, Pollack HM, et al. Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology 1993; 189:339-352 (Pubitemid 23321407)
40. Tamada T, Sone T, Jo Y, et al. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. Radiology 2008; 248:531-539
41. Verma S, Rajesh A. A clinically relevant approach to imaging prostate cancer: review. AJR 2011; 196:S1-S10
42. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243:28-53 (Pubitemid 46579693)
43. Rastinehad AR, Baccala AA Jr, Chung PH, et al. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol 2011; 185:815-820
44. Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: from diagnosis to interventions. RadioGraphics 2011; 31:677-703
45. Just N, Koh DM, D'Arcy J, Collins DJ, Leach MO. Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI. NMR Biomed 2011; 24:902-915
46. Franiel T, Hamm B, Hricak H. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol 2011; 21:616-626
47. Tan CH, Wang J, Kundra V. Diffusion weighted imaging in prostate cancer. Eur Radiol 2011; 21:593-603
48. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261:46-66
49. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012; 61:177-184
50. Salem S, Chang SS, Clark PE, et al. Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. J Urol 2010; 184:1334-1340
51. Girouin N, Mege-Lechevallier F, Tonina Senes A, et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007; 17:1498-1509 (Pubitemid 46767598)
52. Tamada T, Sone T, Higashi H, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR 2011; 197:664-670
53. Tamada T, Sone T, Jo Y, et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. AJR 2011; 197:408-414
54. Bloch BN, Furman-Haran E, Helbich TH, et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging - initial results. Radiology 2007; 245:176-185 (Pubitemid 47417801)
55. Eyal E, Bloch BN, Rofsky NM, et al. Principal component analysis of dynamic contrast enhanced MRI in human prostate cancer. Invest Radiol 2010; 45:174-181